公开(公告)号：AU2020286424A1

公开(公告)日：2022-01-06

申请号：AU2020286424

申请日：2020-05-14

Applicant: VERTEX PHARMA

Inventor： BANDARAGE UPUL KEERTHI ,  BLIGH CAVAN MCKEON ,  BOUCHER DIANE ,  BOYD MICHAEL JOHN ,  BRODNEY MICHAEL AARON ,  CLARK MICHAEL PHILIP ,  DAMAGNEZ VERONIQUE ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  FLEMING GABRIELLE SIMONE ,  GAGNON KEVIN JAMES ,  GARCIA BARRANTES PEDRO MANUEL ,  GIACOMETTI ROBERT DANIEL ,  GIROUX SIMON ,  GREY JR RONALD LEE ,  GUIDO SAMANTHA ,  HALL AMY BETH ,  HOOD SARAH CAROL ,  HURLEY DENNIS JAMES ,  JOHNSON JR MAC ARTHUR ,  JONES PETER ,  KESAVAN SARATHY ,  LAI MEI-HSIU ,  LIU SIYING ,  LOOKER ADAM ,  MAXWELL BRAD ,  MAXWELL JOHN PATRICK ,  MEDEK ALES ,  NUHANT PHILIPPE MARCEL ,  OVERHOFF KIRK ALAN ,  RODAY SETU ,  ROEPER STEFANIE ,  RONKIN STEVEN M ,  SAWANT RUPA ,  SHI YI ,  SHRESTHA MUNA ,  SPOSATO MARISA ,  STAVROPOULOS KATHY ,  SWETT REBECCA JANE ,  TANG QING ,  TAPLEY TIMOTHY LEWIS ,  THOMSON STEPHEN ,  XU JINWANG ,  ZAKY MARIAM ,  COTTRELL KEVIN MICHAEL

IPC: C07D231/56 ,  A61K31/4162 ,  A61K31/429 ,  A61P1/16 ,  A61P11/00 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

公开(公告)号：CO2020000145A2

公开(公告)日：2020-01-17

申请号：CO2020000145

申请日：2020-01-08

Applicant: VERTEX PHARMA

Inventor： HADIDA RUAH SARA SABINA ,  ANDERSON COREY ,  AHMAD NADIA ,  ARUMUGAM VIJAYALAKSMI ,  ASGIAN IULIANA LUCI ,  CAMP JOANNE LOUISE ,  FANNING LEV TYLER DEWEY ,  HURLEY DENNIS ,  SCHMIDT YVONNE ,  SHAW DAVID ,  PATEL URVI ,  THOMSON STEPHEN ANDREW ,  MEIRELES LIDIO MARX CARVALHO

IPC: A61K31/165 ,  A61P29/02 ,  C07C237/42 ,  C07D213/81 ,  C07D213/82

Abstract: RESUMEN Se proporcionan compuestos y sus sales farmacéuticamente aceptables, de utilidad como inhibidores de canales de sodio. Además, se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de varios trastornos, incluyendo dolor.

公开(公告)号：ZA201208373B

公开(公告)日：2014-01-29

申请号：ZA201208373

申请日：2012-11-07

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  BINCH HAYLEY MARIE ,  HURLEY DENNIS JAMES ,  CLEVELAND THOMAS ,  JOSHI PRAMOD ,  FANNING LEV TYLER DEWEY ,  PINDER JOANNE ,  O'DONNELL MICHAEL ,  VIRANI ANISA NIZARALI ,  KNEGTEL RONALD MARCELLUS ALPHONSUS ,  DURRANT STEVEN JOHN ,  YOUNG STEPHEN CLINTON ,  STORCK PIERRE-HENRI ,  KAY DAVID ,  REAPER PHILIP MICHAEL ,  GROTE MATTHEW PAUL

IPC: C07D20060101 ,  A61K20060101 ,  A61P20060101

Abstract: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

公开(公告)号：CA2829803A1

公开(公告)日：2012-09-20

申请号：CA2829803

申请日：2012-03-13

Applicant: VERTEX PHARMA

Inventor： HADIDA-RUAH SARA SABINA ,  BINCH HAYLEY MARIE ,  DENINNO MICHAEL PAUL ,  FANNING LEV TYLER DEWEY ,  FRIEMAN BRYAN A ,  GROOTENHUIS PETER DIEDERIK JAN ,  HILGRAF NICOLE ,  JOSHI PRAMOD ,  KALLEL EDWARD ADAM ,  PONTILLO JOSEPH ,  SILINA ALINA ,  SHETH URVI JAGDISHBHAI ,  HURLEY DENNIS JAMES ,  ARUMUGAM VIJAYALAKSMI ,  MILLER MARK THOMAS

IPC: C07D498/10 ,  A61K31/424 ,  A61P29/00

Abstract: The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

公开(公告)号：CA2798763A1

公开(公告)日：2011-11-17

申请号：CA2798763

申请日：2011-05-12

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  BINCH HAYLEY MARIE ,  HURLEY DENNIS JAMES ,  CLEVELAND THOMAS ,  JOSHI PRAMOD ,  FANNING LEV TYLER DEWEY ,  PINDER JOANNE ,  O'DONNELL MICHAEL ,  VIRANI ANISA NIZARALI ,  KNEGTEL RONALD MARCELLUS ALPHONSUS ,  DURRANT STEVEN JOHN ,  YOUNG STEPHEN CLINTON ,  STORCK PIERRE-HENRI ,  KAY DAVID ,  REAPER PHILIP MICHAEL ,  GROTE MATTHEW PAUL

IPC: C07D413/14 ,  A61K31/444 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I wherein the variables are as defined herein.

公开(公告)号：NZ542664A

公开(公告)日：2009-03-31

申请号：NZ54266404

申请日：2004-03-03

Applicant: VERTEX PHARMA

Inventor： GONZALES JESUS E ,  WILSON DEAN MITCHELL ,  TERMIN ANDREAS PETER ,  GROOTENHUIS PETER DIEDERIK JAN ,  ZHANG YULIAN ,  PETZOLDT BENJAMIN JOHN ,  FANNING LEV TYLER DEWEY ,  NEUBERT TIMOTHY DONALD ,  TUNG ROGER D ,  MARTINBOROUGH ESTHER ,  ZIMMERMANN NICOLE

IPC: A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  C07D20060101 ,  C07D239/91 ,  C07D239/94 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/02 ,  C07D413/12 ,  C07D417/02 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

Abstract: The disclosure relates to quinazoline compounds of formula (IA-ii) useful as inhibitors of voltage-gated sodium channels and calcium channels, wherein the variables are as defined in the specification. Also described are pharmaceutically acceptable compositions comprising the compounds of formula (I) and their use for the manufacture of a medicament for treating or lessening the severity of a disease, disorder, or condition selected from acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or an epilepsy condition, a neurodegenerative disorder, a psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.

公开(公告)号：AU2004217891A1

公开(公告)日：2004-09-16

申请号：AU2004217891

申请日：2004-03-03

Applicant: VERTEX PHARMA

Inventor： FANNING LEV TYLER DEWEY ,  TUNG ROGER D ,  ZHANG YULIAN ,  GONZALES JESUS E III ,  TERMIN ANDREAS PETER ,  NEUBERT TIMOTHY DONALD ,  MARTINBOROUGH ESTHER ,  PETZOLDT BENJAMIN JOHN ,  GROOTENHUIS PETER DIEDERIK JAN ,  WILSON DEAN MITCHELL ,  ZIMMERMANN NICOLE

IPC: A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  C07D20060101 ,  C07D239/91 ,  C07D239/94 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/02 ,  C07D413/12 ,  C07D417/02 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04

Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

公开(公告)号：AU2021358063A9

公开(公告)日：2025-03-13

申请号：AU2021358063

申请日：2021-10-06

Applicant: VERTEX PHARMA

Inventor： MCCARTNEY JASON ,  ABELA ALEXANDER RUSSELL ,  ABRAHAM SUNNY ,  ANDERSON COREY DON ,  ARUMUGAM VIJAYALAKSMI ,  CHAU JACLYN ,  CLEMENS JEREMY ,  CLEVELAND THOMAS ,  COON TIMOTHY RICHARD ,  DWIGHT TIMOTHY A ,  FANNING LEV TYLER DEWEY ,  FRIEMAN BRYAN A ,  GROOTENHUIS PETER (DECEASED) ,  GULEVICH ANTON V ,  HADIDA RUAH SARA SABINA ,  ISHIHARA YOSHIHIRO ,  KHATUYA HARIPADA ,  KRENITSKY PAUL ,  MELILLO VITO ,  MILLER MARK THOMAS ,  PARASELLI PRASUNA ,  PIERRE FABRICE ,  SILINA ALINA ,  TRAN JOE A ,  UY JOHNNY ,  VALDEZ LINO ,  ZHOU JINGLAN

IPC: C07D515/04 ,  A61K31/519 ,  A61P43/00

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

公开(公告)号：CO2021016594A2

公开(公告)日：2022-04-29

申请号：CO2021016594

申请日：2021-12-07

Applicant: VERTEX PHARMA

Inventor： BLIGH CAVAN MCKEON ,  BRODNEY MICHAEL AARON ,  GAGNON KEVIN JAMES ,  HOOD SARAH CAROL ,  LOOKER ADAM ,  MAXWELL JOHN PATRICK ,  MEDEK ALES ,  RODAY SETU ,  ROEPER STEFANIE ,  SAWANT RUPA ,  SHI YI ,  TANG QING ,  BANDARAGE UPUL KEERTHI ,  BOYD MICHAEL JOHN ,  DAMAGNEZ VERONIQUE ,  GIROUX SIMON ,  GREY JR RONALD LEE ,  HALL AMY BETH ,  HURLEY DENNIS JAMES ,  JOHNSON JR MAC ARTHUR ,  JONES PETER ,  KESAVAN SARATHY ,  NUHANT PHILIPPE MARCEL ,  SWETT REBECCA JANE ,  TAPLEY TIMOTHY LEWIS ,  XU JINWANG ,  COTTRELL KEVIN MICHAEL ,  SHRESTHA MUNA ,  BOUCHER DIANE ,  CLARK MICHAEL PHILIP ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  FLEMING GABRIELLE SIMONE ,  GARCIA BARRANTES PEDRO MANUEL ,  GIACOMETTI ROBERT DANIEL ,  GUIDO SAMANTHA ,  LAI MEI-HSIU ,  LIU SIYING ,  MAXWELL BRAD ,  OVERHOFF KIRK ALAN ,  RONKIN STEVEN M ,  SPOSATO MARISA ,  STAVROPOULOS KATHY ,  THOMSON STEPHEN ,  ZAKY MARIAM

IPC: C07D231/56 ,  A61K31/4162 ,  A61K31/429 ,  A61P1/16 ,  A61P11/00 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos.

公开(公告)号：CR20210608A

公开(公告)日：2022-02-11

申请号：CR20210608

申请日：2020-05-14

Applicant: VERTEX PHARMA

Inventor： BLIGH CAVAN MCKEON ,  GUIDO SAMANTHA ,  HOOD SARAH CAROL ,  THOMSON STEPHEN ,  BOYD MICHAEL JOHN ,  DAMAGNEZ VERONIQUE ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  KESAVAN SARATHY ,  MAXWELL JOHN PATRICK ,  OVERHOFF KIRK ALAN ,  STAVROPOULOS KATHY ,  XU JINWANG ,  CLARK MICHAEL PHILIP ,  GAGNON KEVIN JAMES ,  GIACOMETTI ROBERT DANIEL ,  GIROUX SIMON ,  LOOKER ADAM ,  MEDEK ALES ,  FLEMING GABRIELLE SIMONE ,  HURLEY DENNIS JAMES ,  RONKIN STEVEN M ,  SHRESTHA MUNA ,  JONES PETER ,  BOUCHER DIANE ,  BRODNEY MICHAEL AARON ,  GARCIA BARRANTES PEDRO MANUEL ,  NUHANT PHILIPPE MARCEL ,  HALL AMY BETH ,  RODAY SETU ,  SAWANT RUPA ,  SPOSATO MARISA ,  BANDARAGE UPUL KEERTHI ,  JOHNSON JR MAC ARTHUR ,  LAI MEI-HSIU ,  MAXWELL BRAD ,  SWETT REBECCA JANE ,  ZAKY MARIAM ,  COTTRELL KEVIN MICHAEL ,  GREY JR RONALD LEE ,  LIU SIYING ,  ROEPER STEFANIE ,  TANG QING ,  TAPLEY TIMOTHY LEWIS ,  SHI YI

IPC: A61K31/429 ,  A61K31/4162 ,  A61P1/16 ,  A61P11/00 ,  C07D231/56 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos